logo

Stemline Therapeutics Inc (STML)



Trade STML now with
  Date
  Headline
1/18/2019 11:28:13 AM Stemline Therapeutics Closes $92 Mln Public Offering Of Common Stock
1/15/2019 10:07:24 PM Stemline Therapeutics Prices Public Offering Of 8.89 Mln Shares At $9.00/shr
1/14/2019 4:36:41 PM Stemline Therapeutics Announces Proposed Public Offering Of Common Stock
1/7/2019 9:51:26 AM Stemline Therapeutics Announces Submission Of European MAA For ELZONRIS
11/20/2018 7:12:12 AM Stemline Therapeutics Says EMA Grants Accelerated Assessment For Planned ELZONRIS MAA
11/16/2018 7:31:36 AM Stemline Therapeutics Announces Oral Presentation Of SL-701 Phase 2 Data In Second-Line Glioblastoma At SNO
11/12/2018 9:28:26 AM Wedbush Is Cutting Stemline Therapeutics Inc (STML) FY19 Estimate To -1.86 From -1.82
11/12/2018 9:28:12 AM Wedbush Is Cutting Stemline Therapeutics Inc (STML) Q4 19 Estimate To -0.43 From -0.42
11/12/2018 9:27:59 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) Q3 19 Estimate To -0.45 From -0.44
11/12/2018 9:27:49 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) Q2 19 Estimate To -0.46 From -0.44
11/12/2018 9:27:36 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) Q1 19 Estimate To -0.52 From -0.51
11/12/2018 9:27:21 AM Wedbush Is Lowering Stemline Therapeutics Inc (STML) FY18 Estimate To -2.75 From -2.69
11/12/2018 9:27:02 AM Wedbush Is Increasing Stemline Therapeutics Inc (STML) Q4 18 Estimate To -0.67 From -0.68
11/12/2018 9:26:39 AM Wedbush Reiterates Stemline Therapeutics Inc (STML) At Outperform With $22 Price Target
11/2/2018 7:45:17 AM Stemline Therapeutics Reports Four ELZONRIS Presentations, Including An Oral Presentation, At Upcoming ASH Meeting
8/13/2018 6:32:08 AM Stemline Therapeutics Says FDA Accepts ELZONRIS Biologics License Application, Grants Priority Review
8/9/2018 8:14:42 AM Stemline Therapeutics Q2 Net Loss $18.9 Mln Or $0.66/Shr Vs Loss Of $15.5 Mln Or $0.66/Shr Last Year
6/25/2018 7:05:26 AM Stemline Therapeutics Completes Rolling BLA Submission For ELZONRIS For BPDCN
6/18/2018 7:09:00 AM Stemline Therapeutics Announces Positive Clinical Data From ELZONRISTM Trials In BPDCN, CMML And MF
6/15/2018 8:16:53 AM Stemline Announces Presentation Of ELZONRIS Preclinical Data In Systemic Sclerosis, Autoimmune Disorder